Clinical Activity of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and BRCA1 or BRCA2 Mutations Identified by FoundationOne® Liquid CDx (F1L CDx)

Wassim Abida,1 Akash Patmalu,2 David Campbell1, Jeremy Shapiro,1 Alan H. Bryce,1 Ray McDermott,1 Brieuc Sautois,2 Nicholas J. Vogelzang,1 Richard M. Bamberg,4 Eric Vong6, Jinrong Zhang,3 Josef M. Plulata,6 Charles J. Ryan,4,5 Axel S. Merseburger,4 Darrin Despain,7 Andrea Loehr,8 Melanie Dowson,8,9 Tony Goldshleger,10 Simon Chadwick10

1Memorial Sloan Kettering Cancer Center, New York, USA; 2University of Chicago, Chicago, USA; 3Baylor Health University Hospital-Sherman, Sherman, Texas, USA; 4Menlo Innovations, Ann Arbor, Michigan, USA; 5Memorial Sloan Kettering, New York, USA; 6Guarumo Therapeutics, Cambridge, Massachusetts, USA; 7Department of Urology, University of Minnesota, Minneapolis, USA; 8Baylor Health University Hospital-Sherman, Sherman, Texas, USA; 9FoundationOne Europe, Brussels, Belgium; 10University of Minnesota, Minneapolis, USA; 11University Hospital of Liège, CHU, Liège, Belgium; 12University Hospital of Liège, CHU, Liège, Belgium; 13Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France; 14Covis Kinomic, Inc., Boulder, USA; 15Covis Kinomic UK Ltd, Cambridge, UK; 16Guy’s Hospital, London, UK; and 17Sarah Cannon Research Institute, London, UK

SUMMARY

• The PARP inhibitor rucaparib was approved by the US FDA for the treatment of patients with mCRPC and a deleterious BRCA1 or BRCA2 alteration
• FoundationOne® Liquid CDx (F1L CDx) was approved as a plasma-based companion diagnostic to select patients with BRCA+ mCRPC eligible for treatment with rucaparib

• There is high concordance between BRCA status determined from patients’ tissue or by F1L CDx
– Patients with homozgyous loss have high ORR and PSA response rates
• ORR and PSA response rates were similar in patients with mCRPC who were BRCA+ by tissue or by BRCA+ by F1L CDx and similar to the overall response rates

REFERENCES

10. Abida W, Patmalu A, Campbell D, et al. Clinical Activity of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and BRCA1 or BRCA2 Mutations Identified by FoundationOne® Liquid CDx (F1L CDx). J Clin Oncol 2020;38(6):178-190.